A comprehensive scientific review synthesizes the molecular, endocrine, and immunological mechanisms underpinning major pregnancy-related disorders and introduces a unifying conceptual framework termed the Placental-Maternal Adaptation Failure Continuum. Published in Molecular Biomedicine, the work examines how conditions such as preeclampsia, gestational diabetes mellitus, hyperemesis gravidarum, and intrahepatic cholestasis of pregnancy arise not from isolated defects alone, but from dynamic interactions between disorder-specific gestational or fetoplacental stress loads and maternal adaptive reserve. The authors clarify that healthy human pregnancy functions as a physiological stress test, requiring extensive recalibration across metabolic, vascular, hepatic, neuroendocrine, and immune systems to accommodate developing fetoplacental tissues. When the biological challenges imposed by pregnancy exceed maternal compensatory capacities across these physiological domains, clinical maladaptation emerges. The framework organizes these multifactorial disorders while preserving their distinct diagnostic boundaries, specifically clarifying that the model serves as an evidence-organizing heuristic rather than a validated predictive or clinical diagnostic algorithm.
Healthy gestation relies on coordinated organ-system adaptations to support fetal growth while safeguarding maternal homeostasis. During normal gestation, maternal plasma volume expands by approximately 40% to 50% while systemic blood pressure is maintained through a concurrent reduction in systemic vascular resistance. Hemodynamic remodeling is promoted in part by relaxin acting via the RXFP1 receptor on endothelial and vascular smooth muscle cells, stimulating endothelial nitric oxide synthase phosphorylation and nitric oxide production. At the maternal-fetal interface, extravillous trophoblasts invade the decidua and inner myometrium, undergoing an integrin switch from alpha-6-beta-4 toward alpha-1-beta-1 and alpha-5-beta-1 while acquiring vascular mimicry features that include VE-cadherin and VCAM-1 expression. This invasive process converts narrow, muscular spiral arteries into low-resistance vascular conduits. Concurrently, specialized immune circuits prevent alloimmune rejection of the semi-allogeneic fetus. Extravillous trophoblasts selectively express nonclassical human leukocyte antigen G, which binds inhibitory receptors LILRB1 and KIR2DL4 on uterine natural killer cells to promote pro-angiogenic mediators such as VEGF-C, PlGF, and Ang-2, while trophoblast and decidual antigen-presenting cells express indoleamine 2,3-dioxygenase to metabolize tryptophan into kynurenine, fostering regulatory T-cell differentiation.
Metabolic and hepatobiliary systems likewise undergo marked reprogramming during uncomplicated gestation. Maternal metabolism exhibits a biphasic trajectory, beginning with an anabolic storage phase before transitioning after approximately 20 weeks to a catabolic state characterized by physiological insulin resistance. By the third trimester, maternal insulin sensitivity declines by roughly 50% to 70%, driven by rising levels of human placental lactogen and placental growth hormone that diminish post-receptor IRS-PI3K-Akt signaling in skeletal muscle and adipose tissue. This controlled reduction in peripheral maternal glucose uptake preserves circulating glucose for concentration-dependent transfer to the fetus across placental GLUT1 transporters. Maternal pancreatic beta cells compensate by expanding insulin output, supported in part by prolactin receptor signaling via the JAK2-STAT5 pathway. In the liver, bile acid clearance is maintained despite elevated gestational steroid hormones. Activation of the farnesoid X receptor sustains expression of the ABCB11 gene encoding the bile salt export pump, counteracting physiological pressures from rising estrogen and sulfated progesterone metabolites that otherwise impede canalicular transporter transcription and export function.
Within the proposed adaptation failure continuum, clinical disorders are conceptualized through a two-hit model representing the interaction between a disorder-relevant gestational or fetoplacental stress load and maternal adaptive reserve. Hit 1 encompasses directly placenta-derived signals, the cumulative physiological demands of fetal growth, and secondary maternal or fetal mediators, whereas Hit 2 reflects maternal vulnerability arising from limited capacity within vascular, metabolic, hepatic, neuroendocrine, or immune systems to buffer these stresses. The authors emphasize that these two components interact dynamically and non-sequentially rather than as fixed temporal stages. When maternal reserve is robust, substantial gestational stress loads may remain clinically compensated; conversely, when underlying maternal reserve is markedly compromised by pre-existing microvascular disease, metabolic dysfunction, or genetic variation, even modest gestational demands can exceed the conceptual adaptation threshold and trigger overt clinical pathology.
In preeclampsia, the continuum illustrates how placenta-derived stress factors challenge maternal vascular and endothelial reserve. Incomplete spiral artery remodeling and impaired trophoblast invasion can generate intermittent placental perfusion and hypoxia-reoxygenation stress. Stabilized hypoxia-inducible factors, particularly HIF-2alpha, stimulate trophoblast transcription of the anti-angiogenic factor soluble fms-like tyrosine kinase-1, including placenta-enriched splice variants such as sFlt-1-e15a. Circulating sFlt-1 sequesters vascular endothelial growth factor and placental growth factor, depriving maternal endothelial cells of critical survival signals, while shed soluble endoglin interferes with downstream BMP9 and TGF-beta signaling pathways. Concurrently, stressed syncytiotrophoblasts shed extracellular vesicles and damage-associated molecular patterns, such as HMGB1 and cell-free fetal DNA, which engage Toll-like receptors 4 and 9 to trigger inflammatory cascades. When maternal endothelial reserve is impaired by chronic hypertension, obesity, or oxidative stress, oxidation of the eNOS cofactor tetrahydrobiopterin leads to eNOS uncoupling and superoxide generation. This endothelial injury impairs glycocalyx integrity, disrupts glomerular slit diaphragms, and produces clinical hypertension, proteinuria, and systemic end-organ damage.
Gestational diabetes mellitus reflects a parallel failure of metabolic adaptation, where gestational insulin resistance outstrips maternal pancreatic compensatory capacity. Placental hormones, inflammatory cytokines like TNF-alpha, and placenta-derived extracellular vesicles carrying microRNA cargo impair maternal IRS1 phosphorylation and peripheral glucose disposal. If maternal metabolic reserve is constrained by genetic variants in loci such as TCF7L2, GCK, or MTNR1B, or by obesity-associated adipose tissue inflammation marked by macrophage crown-like structures, pancreatic beta cells fail to sustain adequate insulin hypersecretion. The resulting maternal hyperglycemia increases glucose transfer across the placenta, stimulating fetal hyperinsulinemia. The review notes that human placental studies link elevated insulin and mTORC1 activation to increased amino acid transport and fetal overgrowth, consistent with the revised Pedersen framework, though a direct self-amplifying fetoplacental feedback loop remains unproven in human pregnancy.
The framework similarly clarifies neuroendocrine and hepatobiliary vulnerabilities in hyperemesis gravidarum and intrahepatic cholestasis of pregnancy. In hyperemesis gravidarum, the primary driver within Hit 1 is fetoplacental production of growth differentiation factor 15, which circulates at increased concentrations during gestation and binds GFRAL-RET receptor complexes concentrated in the hindbrain area postrema and nucleus tractus solitarius. Maternal vulnerability appears partly governed by pre-pregnancy GDF15 exposure, where lower baseline exposure confers heightened sensitivity to the gestational hormone surge. In intrahepatic cholestasis of pregnancy, elevated gestational estrogen and sulfated progesterone metabolites suppress farnesoid X receptor signaling and inhibit bile salt export pump activity. When combined with maternal genetic variations in ABCB11 or ABCB4 that diminish canalicular bile acid or phosphatidylcholine export capacity, canalicular transport becomes bottlenecked. This defect allows toxic bile acids to accumulate in maternal circulation and potentially trigger fetal cardiac dysfunction via altered cardiomyocyte calcium handling, although arrhythmogenic fetal demise remains an experimental finding rather than an established sole cause of death in humans.
The review also introduces the concept of pregnancy memory, which posits that severe maladaptation during gestation may leave persistent cellular, epigenetic, or structural imprints contributing to elevated long-term maternal cardiometabolic disease. Clinical epidemiological studies demonstrate that women with a history of preeclampsia or gestational diabetes experience significantly higher rates of future chronic hypertension, cardiovascular events, and type 2 diabetes. Proposed biological mechanisms include persistent leukocyte epigenetic remodeling, maladaptive vascular repair, vascular stiffness, and low-grade metabolic inflammation. However, the authors explicitly emphasize that existing evidence cannot fully separate pregnancy-induced reprogramming from pre-existing baseline vulnerability and shared cardiometabolic risk factors. Furthermore, while conditions like severe hyperemesis gravidarum may deplete maternal nutritional and hepatic reserves, cross-disorder associations represent shared susceptibilities and secondary physiological stresses rather than deterministic causal progressions from one disorder into another.
Translational and therapeutic strategies are strictly classified across defined evidence tiers to distinguish routine clinical standards from exploratory interventions. Established clinical care remains anchored in guideline-based, disease-specific protocols: preeclampsia management relies on blood pressure monitoring, laboratory assessments, and indicated delivery; gestational diabetes requires medical nutrition therapy and glycemic surveillance; hyperemesis gravidarum focuses on rehydration, thiamine, and antiemetics; and cholestasis centers on biochemical monitoring and delivery planning. Among molecular markers, the sFlt-1/PlGF ratio serves as a validated clinical adjunct for short-term preeclampsia rule-out in selected pathways, whereas circulating cell-free RNA signatures, chromosome 19 microRNA clusters, and polygenic risk scores remain investigational tools limited by pre-analytical variability and ancestry transferability. Emerging therapeutics likewise occupy early developmental stages, including dextran sulfate apheresis with limited human pilot evidence, the sFLT1-targeting small interfering RNA CBP-4888 in phase 1 evaluation, the GFRAL-antagonist antibody NGM120 in phase 2 trials, and chemical chaperones like 4-phenylbutyrate for BSEP trafficking rescue in preclinical evaluation.
The authors conclude that translating the continuum into clinical utility will require rigorous prospective longitudinal studies initiated prior to disease onset. Repeated biological sampling across gestation and the postpartum period is needed to distinguish genuine indicators of adaptive reserve from markers of active tissue injury. Because pregnancy profoundly alters maternal pharmacokinetics, drug distribution, and organ clearance, novel molecular interventions must undergo stringent maternal-fetal safety evaluations and demonstrate added benefit beyond standard clinical management without overriding established indications for delivery. Until dynamic reserve thresholds and mechanistic interventions are prospectively validated across diverse ancestral and socioeconomic populations, clinical practice must remain grounded in established disease-specific guidelines, while the continuum provides a structured heuristic to guide future translational investigation.
Subject of Research: Systemic molecular mechanisms and adaptive failure framework across pregnancy-related disorders
Article Title: Pregnancy-related disorders: molecular mechanisms and management
Article References: Lee, C., Zhu, C., Li, Y., Yang, J., Zhang, X., Jiang, W., Mou, D., Li, H., & Hu, Q. (2026). Pregnancy-related disorders: molecular mechanisms and management. Molecular Biomedicine, 7(1), Article 204. https://doi.org/10.1186/s43556-026-00566-6
Image Credits: AI Generated
DOI: 10.1186/s43556-026-00566-6
Keywords: preeclampsia, gestational diabetes mellitus, hyperemesis gravidarum, intrahepatic cholestasis of pregnancy, placental-maternal adaptation failure continuum, sFlt-1/PlGF ratio, growth differentiation factor 15, bile salt export pump, endothelial dysfunction, pancreatic beta-cell compensation, pregnancy memory, uterine natural killer cells, extravillous trophoblast invasion, hemodynamic adaptation, farnesoid X receptor, investigational biomarkers
Cite Scienmag News
Drew Townsend. (November 20, 2026). New Framework Models How Maternal Organs Fail Under Gestational Stress. Scienmag. https://scienmag.com/new-framework-models-how-maternal-organs-fail-under-gestational-stress/
Drew Townsend. "New Framework Models How Maternal Organs Fail Under Gestational Stress." Scienmag, 20 November 2026, https://scienmag.com/new-framework-models-how-maternal-organs-fail-under-gestational-stress/. Accessed 20 November 2026.
Drew Townsend. "New Framework Models How Maternal Organs Fail Under Gestational Stress." Scienmag. November 20, 2026. https://scienmag.com/new-framework-models-how-maternal-organs-fail-under-gestational-stress/








